A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3462-9.